CN103251552B - 一种恩诺沙星糊剂及其制备方法 - Google Patents
一种恩诺沙星糊剂及其制备方法 Download PDFInfo
- Publication number
- CN103251552B CN103251552B CN201310210209.6A CN201310210209A CN103251552B CN 103251552 B CN103251552 B CN 103251552B CN 201310210209 A CN201310210209 A CN 201310210209A CN 103251552 B CN103251552 B CN 103251552B
- Authority
- CN
- China
- Prior art keywords
- parts
- cataplasm
- enrofloxacin
- piglet
- vaseline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229960000740 enrofloxacin Drugs 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 229940099259 vaseline Drugs 0.000 claims abstract description 10
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000003254 palate Anatomy 0.000 abstract description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000002268 wool Anatomy 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229950005162 benexate Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- -1 dispersing aid Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310210209.6A CN103251552B (zh) | 2013-05-30 | 2013-05-30 | 一种恩诺沙星糊剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310210209.6A CN103251552B (zh) | 2013-05-30 | 2013-05-30 | 一种恩诺沙星糊剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103251552A CN103251552A (zh) | 2013-08-21 |
CN103251552B true CN103251552B (zh) | 2014-12-31 |
Family
ID=48955997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310210209.6A Expired - Fee Related CN103251552B (zh) | 2013-05-30 | 2013-05-30 | 一种恩诺沙星糊剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103251552B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105147706A (zh) * | 2015-09-22 | 2015-12-16 | 古东晖 | 一种皮肤杀菌止痒组合物及其制备方法和用途 |
ITUB20161210A1 (it) * | 2016-02-10 | 2017-08-10 | Dioni Lorena | Associazione zucchero e vaselina e suo uso nelle ferite |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19633480A1 (de) * | 1996-08-20 | 1998-02-26 | Bayer Ag | Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren |
CN102614194B (zh) * | 2012-03-15 | 2014-06-11 | 济南龙华医药技术有限公司 | 一种含二氟拉松、阿达帕林和阿维a的治疗皮肤病的外用药物及其应用 |
-
2013
- 2013-05-30 CN CN201310210209.6A patent/CN103251552B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103251552A (zh) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101810627B (zh) | 复方磺胺间甲氧嘧啶或复方磺胺间甲氧嘧啶钠注射液及制备方法 | |
CN108815123A (zh) | 一种姜黄素固体分散体及其制备方法和应用 | |
CN101401787A (zh) | 一种头孢噻呋长效注射液及其制备方法 | |
CN102743333A (zh) | 一种左乙拉西坦口服液及其制备方法 | |
CN101579347B (zh) | 治疗泌乳期奶牛乳房炎的乳房灌注剂及其制备方法 | |
CN104814931B (zh) | 一种喹乙醇缓释颗粒及其制备方法和应用 | |
CN103251552B (zh) | 一种恩诺沙星糊剂及其制备方法 | |
CN107898767B (zh) | 一种犬用盐酸二甲双胍缓释咀嚼片及其制备方法 | |
CN103271931B (zh) | 复方酒石酸泰万菌素微丸及其制备方法 | |
CN105030665B (zh) | 一种兽用长效盐酸林可霉素注射液及其制备方法 | |
CN1679763A (zh) | 夏桑菊凝胶制剂及其制备方法 | |
CN103622987A (zh) | 一种兽用长效复方盐酸林可霉素注射液及其制备方法 | |
CN102440998A (zh) | 一种复方盐酸多西环素混悬注射剂及其制备方法 | |
CN105147598A (zh) | 一种兽用乳酸环丙沙星注射液及其制备方法 | |
CN105496951A (zh) | 一种缓释恩诺沙星注射液的制备方法 | |
CN104610281B (zh) | 头孢噻呋镁及其制备和使用方法 | |
US20190008967A1 (en) | Oil suspension of metronidazole | |
CN102258479B (zh) | 一种骨钙素的注射用缓释微球制剂 | |
CN102973755A (zh) | 治疗畜禽蛔虫病和绦虫病的组合物及其制备方法 | |
CN103222958A (zh) | 一种阿德呋啉的抗球虫干混悬剂及其制备方法 | |
CN103127178A (zh) | 一种治疗禽畜肠道感染的药物及其制备方法 | |
CN102266284A (zh) | 塞克硝唑阴道栓剂及其制备工艺 | |
CN101161652B (zh) | 具有抗菌活性的喹嗪类衍生物 | |
CN105496949A (zh) | 一种缓释左氧氟沙星注射液的制备方法 | |
CN105412124A (zh) | 兽用维生素ad3e乳剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130821 Assignee: Chengdu Kunhong Animal Pharmacy Group Co., Ltd. Assignor: Chengdu Qiankun Animal Pharmaceutical Co.,Ltd. Contract record no.: 2015510000126 Denomination of invention: Enrofloxacin cataplasm and preparation method thereof Granted publication date: 20141231 License type: Exclusive License Record date: 20150827 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 611130 Wenjiang, Chengdu, Chengdu cross strait science and Technology Industrial Development Zone, Jin Fu Road, Sichuan Patentee after: Chengdu Qiankun animal pharmaceutical Limited by Share Ltd Address before: 611130 Wenjiang, Chengdu, Chengdu cross strait science and Technology Industrial Development Zone, Jin Fu Road, Sichuan Patentee before: Chengdu Qiankun Animal Pharmaceutical Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141231 Termination date: 20190530 |